Intermune (ITMN) April volatility elevated into expected IBF drug decision
Tweet Send to a Friend
Intermune (Nasdaq: ITMN) is waiting for the EU approval of pirfenidone to treat ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
